Clinical Trials
16 trialsNCT03267433 2026-05-05
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Phase 3 Active not recruiting
NCT04870944 2026-05-05
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
Children's Oncology Group
Phase 1/2 Recruiting
NCT03660826 2026-05-04
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07174128 2026-04-21
Two Cut-Off Values of Plethysmographic Variability Index to Guide Intraoperative Fluid Therapy on Serum Lactate in Patients Undergoing Excision of Supra-Tentorial Brain Tumors
Cairo University
Phase NA Completed
NCT07144826 2026-02-13
Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT05847569 2026-02-03
Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma
Mayo Clinic
Phase 2 Recruiting
NCT06013423 2026-01-22
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Fred Hutchinson Cancer Center
Phase 2 Recruiting
NCT04659616 2025-12-19
Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia
OHSU Knight Cancer Institute
Phase 1 Recruiting
NCT06672224 2025-09-17
Indocyanine Green Fluoroscopy and SPY Angiography for the Assessment of Lymphatic Structure in Breast Cancer Patients at Risk for Breast Cancer-Related Lymphedema
City of Hope Medical Center
Phase NA Withdrawn
NCT03941860 2025-05-23
Testing the Addition of Ixazomib/Placebo to Lenalidomide in Patients With Evidence of Residual Multiple Myeloma, OPTIMUM Trial
National Cancer Institute (NCI)
Phase 3 Completed
NCT04987463 2024-02-08
ViRap
Children's Memorial Health Institute, Poland
Phase 2/3 Unknown
NCT02257567 2022-11-14
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
Phase 1/2 Completed
NCT03062059 2022-04-14
The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence
National Cancer Center, Korea
Phase 2 Unknown
NCT02100969 2021-06-02
Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis
University of Kansas Medical Center
Phase 2 Completed
NCT01132755 2019-06-14
Rapid Gastric and Pancreas Cancer Staging Utilizing Peritoneal Lavage
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00667485 2014-01-17
Rapamycin Plus Bevacizumab in Advanced Cancers
University of Chicago
Phase 1 Completed